Michel Goldman is specialised in immunology and internal medicine. He is the Executive Director of the Institute for Interdisciplinary Innovation in healthcare (I3h) and Full Professor at the ULB.
From 2009-2014, he was the first Executive Director of the Innovative Medicines Initiative Joint Undertaking, a €2 billion partnership between the European Federation of Pharmaceutical Industries and Associations and the European Commission.
He is a member of the Board of Directors of the Canadian Consortium for Precompetitive Pharmaceutical Research, the European Tuberculosis Vaccine Initiative and the French National Institute of Health and Medical Research.
His scientific achievements resulted in a recognition as ISI Highly Cited Scientist by the Thomson Institute. He was also the laureate of the Quinquennial Prize of the Belgian National Fund of Scientific Research for Clinical Sciences (2000) and he held the Spinoza chair at the University of Amsterdam (2001).